Evidence before this study
death, SARS-CoV-2 infection
SARS-COV-2 INFECTION
Immunocompromised patients have increased risk for severe COVID-19 and COVID-19-associated death and respond variably to SARS-CoV-2 mRNA vaccination. Limited information comparing different immunocompromised patient groups with respect to long-term immunogenicity following three and four vaccine doses, particularly in studies that take SARS-CoV-2 infection into consideration, is available. In support of this notion, on March 27, 2023, we searched PubMed for “Clinical Trials” with the following search criteria: (“SARS-CoV-2” OR “COVID-19”) AND (“immunocompromised” OR “immunodeficient”) AND (“vaccination”) AND (“mRNA”). The query returned eight clinical trials. None of the clinical trials identified investigated long-term immunity (>2 months following primary vaccination), the effect of booster doses, and SARS-CoV-2 infection in relation to immunogenicity. Notably, however, other related search criteria returned additional studies related to the present topic.